Last reviewed · How we verify

NCT04349839

ACRODAT Prospective Evaluation Study

Status unknown Last updated 4 December 2023
What this trial tests

trial testing Acrodat software in Acromegaly in 500 participants. Status unknown.

Timeline
15 January 2020
Primary endpoint
1 October 2023
1 February 2025

Quick facts

Lead sponsorUniversity of Aarhus
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date15 January 2020
Primary completion1 October 2023
Estimated completion1 February 2025
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Aarhus

Who can join

Adults 18 to 99, any sex, with Acromegaly. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ACRODAT® is a new software medical device developed by a group of acromegaly experts to help practising endocrinologists assess disease activity in patients with acromegaly. It uses 5 key parameters (IGF-I level, tumour status, comorbidities, symptoms and Quality of life) to evaluate the patient's health status. The purpose of this post marketing surveillance study is to prospectively evaluate whether patients monitored by ACRODAT® with appropriate clinical decisions based on disease activity status will benefit from improved treatment outcomes both in the short and in the long term.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acromegaly

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04349839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing